{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8","value":"96"},{"groupId":"OG001","spread":"23","value":"91"},{"groupId":"OG002","spread":"4","value":"98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"These data are based on patient diaries. For children \\<3 years of age, we will calculate the percentage of total scheduled doses each patient received per course for each of the oral maintenance courses and report the overall average number percentage of doses received per course across patients. If patients received all planned doses, their percentage would be 100%. If the average percentage was less than 75%, then feasibility would be in question.","dispersionType":"Standard Deviation","groups":[{"description":"Patients \\<3 years of age with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients \\<3 years of age with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients \\<3 years of age with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients less than 3 years of age (n=273) constituted the study population for this analysis; 167 of these patients started the first course of maintenance and were included in this analysis (50 low-risk, 87 intermediate-risk, and 30 high-risk patients).","reportingStatus":"POSTED","timeFrame":"From start of oral maintenance therapy (approximately 6 months after on-study date) to completion of oral maintenance therapy (up to 1 year after on-study date)","title":"Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children <3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received","type":"SECONDARY","unitOfMeasure":"Percentage of scheduled doses received"}